Yesterday, Nov. 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $15.70 to $16,136,040.00.

Highlighted Stocks Traded by Insiders:

Rouse Properties (RSE) - FREE Research Report

Kruth David, who is Director at Rouse Properties, bought 500 shares at $16.00 on Nov. 19, 2015. Following this transaction, the Director owned 21,163 shares meaning that the stake was boosted by 2.42% with the 500-share transaction.

The shares most recently traded at $16.21, up $0.21, or 1.3% since the insider transaction. Historical insider transactions for Rouse Properties go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 8,871
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 8,871
  • 24-Week # shares bought: 11,825
  • 24-Week # shares sold: 8,871

The average volume for Rouse Properties has been 264,300 shares per day over the past 30 days. Rouse Properties has a market cap of $944.0 million and is part of the financial sector and real estate industry. Shares are down 11.99% year-to-date as of the close of trading on Thursday.

Rouse Properties, Inc. owns and manages regional malls in the United States. Its portfolio consists of 30 regional malls in 19 states totaling approximately 21 million square feet of retail and ancillary space. The company is based in New York, New York. Rouse Properties, Inc. The stock currently has a dividend yield of 4.43%. The company has a P/E ratio of 31.3. Currently, there are 2 analysts who rate Rouse Properties a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RSE - FREE

TheStreet Quant Ratings rates Rouse Properties as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow, poor profit margins and a generally disappointing performance in the stock itself. Get the full Rouse Properties Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Maximus (MMS) - FREE Research Report

Pond Peter, who is Director at Maximus, bought 14,375 shares at $52.27 on Nov. 19, 2015. Following this transaction, the Director owned 14,375 shares meaning that the stake was boosted by 100% with the 14,375-share transaction.

The shares most recently traded at $53.64, up $1.37, or 2.55% since the insider transaction. Historical insider transactions for Maximus go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 21,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 21,000

The average volume for Maximus has been 487,000 shares per day over the past 30 days. Maximus has a market cap of $3.4 billion and is part of the services sector and diversified services industry. Shares are down 5.49% year-to-date as of the close of trading on Thursday.

MAXIMUS, Inc. provides business process services to government health and human services agencies in the United States, Australia, Canada, the United Kingdom, and Saudi Arabia. The company operates through two segments, Health Services and Human Services. The stock currently has a dividend yield of 0.34%. The company has a P/E ratio of 22.4. Currently, there are 4 analysts who rate Maximus a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMS - FREE

TheStreet Quant Ratings rates Maximus as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Maximus Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DENTSPLY International (XRAY) - FREE Research Report

Rasin Deborah, who is VP,Secretary & General Counsel at DENTSPLY International, sold 4,500 shares at $60.56 on Nov. 19, 2015. Following this transaction, the VP,Secretary & General Counsel owned 4,429 shares meaning that the stake was reduced by 50.4% with the 4,500-share transaction.

The shares most recently traded at $61.20, up $0.64, or 1.05% since the insider transaction. Historical insider transactions for DENTSPLY International go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 2,500
  • 24-Week # shares sold: 2,500

The average volume for DENTSPLY International has been 1.3 million shares per day over the past 30 days. DENTSPLY International has a market cap of $8.5 billion and is part of the health care sector and health services industry. Shares are up 14.68% year-to-date as of the close of trading on Thursday.

DENTSPLY International Inc. designs, develops, manufactures, and markets various consumable dental products for the professional dental market in the United States and internationally. The stock currently has a dividend yield of 0.48%. The company has a P/E ratio of 31.4. Currently, there are 7 analysts who rate DENTSPLY International a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on XRAY - FREE

TheStreet Quant Ratings rates DENTSPLY International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full DENTSPLY International Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.